Immunoprevention of cancer: Is the time ripe?

Cancer Research

Volumn 60, Issue 10, 2000, Pages 2571-2575

  Forni, Guido ^a   Lollini, Pier Luigi ^b   Musiani, Piero ^c   Colombo, Mario P ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; GENETIC RISK; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; PRIORITY JOURNAL; REVIEW;

HUMANS; IMMUNIZATION; NEOPLASMS;

EID: 0034658656     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Riethmuller, G., Holz, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Funke, I., Pichlmaier, H., Hirche, K., Buggisch, P., Witte, J., and Pichlmayr, R. Monoclonal antibody therapy for resected Dukes' C colorectel cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
2. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., and Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 18: 219-230, 1999.
3. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
4. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R. Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmore, S. P., Longo, D. L., and Kwak, L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 5: 1171-1177, 1999.
5. Boon, T., Cerottini, J-C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
6. Pfreundschuh, M., Shiku, H., Takahashi, T., Ueda, R., Ransohoff, J., Oettgen, H. F., and Old, L. J. Serological analysis of cell surface antigens of malignant human brain tumors. Proc. Natl. Acad. Sci. USA, 75: 5122-5126, 1978.
7. Rosenthal, A. S., and Shevach, E. M. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J. Exp. Med., 138: 1194-1212, 1973.
8. Townsend, A. R., Bastin, J., Gould, K., and Brownlee, G. G. Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence. Nature (Lond.), 324: 575-577, 1986.
9. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime CTL against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
10. Allison, J. P. CD28-B7 interactions in T-cell activation. Curr. Opin. Immunol., 6: 414-419, 1994.
11. Matzinger, P. An innate sense of danger. Semin. Immunol., 10: 399-415, 1998.
12. Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M. P., Lollini, P-L., and Forni, G. Cytokines, tumor cell death and immunogenicity: a question of choice. Immunol. Today, 18: 32-36, 1997.
13. Fell, H. P., Gayle, M. A., Grosmaire, L., and Ledbetter, J. A. Genetic construction and characterization of a fusion protein consisting of chimeric F(ab′) with specificity for carcinomas and human 1L-2. J. Immunol., 146: 2446-2452, 1991.
14. Moro, M., Gasparri, A. M., Pagano, S., Bellone, M., Tornaghi, P., Veglia, F., Corti, A., Casorati, G., and Dellabona, P. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules. Cancer Res., 59: 2650-2656, 1999.
15. Sturmhoefel, K., Lee, K., Gray, G. S., Thomas, J., Zollner, R., O'Toole, M., Swiniarski, H., Dorner, A., and Wolf, S. F. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res., 59: 4964-4972, 1999.
16. Prigent, P., El Mir, S., Dreano, M., and Triebel, F. Lymphocyte activation gene-3 induces tumor regression and tumor immune responses. Eur. J. Immunol., 29: 3867-3876, 1999.
17. Colombo, M. P., and Forni, G. Immunotherapy. I. Cytokine gene transfer strategies. Cancer Metastasis Rev., 15: 317-328, 1996.
18. Zitvogel, L., Couderc, B., Mayordomo, J. I., Robbins, P. D., Lotze, M. T., and Storkus, W. J. IL-12-engineered dendritic cells serve as effeclive tumor vaccine adjuvants in vivo. Ann. N. Y. Acad. Sci., 795: 284-293, 1996.
19. Colombo, M. P., and Forni, G. Cytokine gene transfer in tumor inhibition and tentative tumor therapy: where are we now? Immunol. Today, 15: 48-51, 1994.
20. de Gruijl, T. D., and Curiel, D. T. Cancer vaccine strategies get bigger and better. Nat. Med., 5: 1124-1125, 1999.
21. Nanni, P., Forni, G., and Lollini, P-L. Cytokine gene therapy: hopes and pitfalls. Ann. Oncol., 10: 261-266, 1999.
22. Fishel, R. Genomic instability, mutation, and the development of cancer: is there a role for p53? J. Natl. Cancer Inst., 88: 1608-1609, 1996.
23. Riker, A., Cormier, J., Panelli, M., Kammula, U., Wang, E., Abati, A., Fetsch, P., Lee, K. H., Steinberg, S., Rosenberg, S., and Marincola, F. Immune selection after antigen-specific immunotherapy of melanoma. Surgery (St Louis), 126: 112-120, 1999.
24. Singh, S., Ross, S. R., Acena, M., Rowley, D. A., and Schreiber, H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med., 175: 139-146, 1992.
25. Piali, L., Fichtel, A., Terpe, H. J., Imhof, B. A., and Gisler, R. H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med., 181: 811-816, 1995.
26. Horiguchi, S., Petersson, M., Nakazawa, T., Kanda, M., Zea, A. H., Ochoa, A. C., and Kiessling, R. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res., 59: 2950-2956, 1999.
27. Cavallo, F., Di Carlo, E., Butera, M., Verrua, R., Colombo, M. P., Musiani, P., and Forni, G. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic IL-12. Cancer Res., 59: 414-421, 1999.
28. Berd, D. Cancer vaccines: reborn or just recycled? Semin. Oncol., 25: 605-610, 1998.
29. Dranoff, G., and Mulligan, R. C. Gene transfer as cancer therapy. Adv. Immunol., 58: 417-454, 1995.
30. Lollini, P-L., and Forni, G. Specific and non-specific immunity in the prevention of spontaneous tumors in person at risk. Immunol. Today, 20: 343-347, 1999.
31. Hargest, R., and Williamson, R. Prophylactic gene therapy for cancer. Gene Ther., 3: 97-102, 1996.
32. Thomasset, N., Lochter, A., Sympson, C. J., Lund, L. R., Williams, D. R., Behrendtsen, O., Werb, Z., and Bissell, M. J. Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am. J. Pathol., 153: 457-467, 1998.
33. Onrust, S. V., Hartl, P., Rosen, S. D., and Hannahan, D. Modulation of L-selectin ligand expression during an immune response accompanying tumorigenesis in transgenic mice. J. Clin. Invest., 97: 54-64, 1996.
34. Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M., Rossi, I., Nanni, P., De Giovanni, C., Bouchard, P., Wolf, S., Modesti, A., Musiani, P., Lollini, P-L., Colombo, M. P., and Forni, G. Interleukin-12 mediated prevention of spontaneous mammary adenocarcinomas in two lines of HER2/neu transgenic mice. J. Exp. Med., 188: 589-596, 1998.
35. Siegel, P. M., Ryan, E. D., Cardiff, R. D., and Muller, W. J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J., 18: 2149-2164, 1999.
36. Lappé, M. A. Evidence for the antigenicity of papillomas induced by 3-methylcholanthrene. J. Natl. Cancer Inst., 40: 823-846, 1968.
37. Noguchi, Y., Jungblut, A., Richards, E. C., and Old, L. L. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc. Natl. Acad. Sci. USA, 93: 11798-11801, 1998.
38. Jonsen, R. A., Durfy, S. J., Burke, W., and Motulsky, A. G. The advent of the "impatient." Nat. Med., 2: 622-624, 1966.
39. Goldstein, L. J. Breast cancer research. In: Fox Chase Cancer Center Scientific Report, pp. 143-144. Philadelphia: Fox Chase Cancer Center, 1998.
40. Sukumar, S., and McKenzie, K. Breast cancer prevention strategies for the twenty-first century. Mol. Med. Today, 2: 453-459, 1996.
41. Lapṕ, M. A., and Prehn, R. T. Immunologic surveillance at the macroscopic level: nonselective elimination of premalignant skin papillomas. Cancer Res., 29: 2374-2378, 1969.
42. Boggio, K., Di Carlo, E., Rovero, S., Cavallo, F., Quaglino, E., Lollini, P-L., Nanni, P.. Nicoletti, G., Wolf, S., Musiani, P., and Forni, G. Ability of systemic IL-12 to hamper progressive stages of mammary carcinogenesis in Her2/neu transgenic mice. Cancer Res., 60: 359-364, 2000.
43. Disis, M. L., and Cheever, M. A. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol., 8: 637-642, 1996.
44. Amid, A., Venanzi, F. M., and Concetti, A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol. Immunother., 47: 183-190, 1998.
45. Cefai, D., Morrison, B. W., Sckell, A., Favre, L., Balli, M., Leunig, M., and Gimmi, C. D. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int. J. Cancer, 29: 393-400, 1999.
46. Esserman, L. J., Lopez, T., Montes, R., Bald, L. N., Fendly, B. M., and Campbell, M. J. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother., 47: 337-342, 1999.
47. Huang, K., and Lin, S. Nationwide vaccination. A success story in Taiwan. Vaccine, 18 (Suppl. 1): S35-S38, 2000.
48. Jensen, E. R., Selvakumar, R., Shen, H., Ahmend, R., Wettstein, F. O., and Miller, J. F. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol., 71: 8467-8474, 1997.
49. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W., Westmoreland, D., Evans, A. S., Adams, M., Stacey, S. N., Boursnell, M. E., Ruthergford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccinia virus encoding human papilomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347: 1523-1527, 1996.
50. Vonderheide, R. H., Hahn, W. C., Schultze, J. L., and Nadler, L. M. The telomerase catalytic subunit is a widely expressed tumor associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10: 673-679, 1999.
51. Hesketh, R. Oncogene and Tumor Suppressor Gene Facts Book. San Diego, CA: Academic Press, 1997.
52. Hu, J., Kindsvogel, W., Busby, S., Bailey, M. C., Shi, Y. Y., and Greenberg, P. D. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing retoviral tumor antigen in normal lymphoid tissues. J. Exp. Med., 177: 1681-1690, 1993.
53. Pardoll, D. M. Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA, 96: 5340-5342, 1999.
54. Chan, L. S., Vanderlugt C. J., Hashimoto, T., Nishikawa, T., Zone, J. J., Black, M. M., Wojnarowska, F., Stevens, S. R., Chen, M., Fairley, J. A., Woodley, D. T., Miller, S. D., and Gordon, K. B. Epilope spreading: lessons from autoimmune skin diseases. J. Invest. Dermatol., 110: 103-109, 1998.
55. Nanni, P., De Giovanni, C., Landuzzi, L., Nicoletti, G., Frabetti, F., Rossi, I., Cavallo, F., Giovarelli, M., Forni, G., and Lollini, P-L. Therapy of murine mammary carcinoma metastasis with interferon γ and MHC gene-transduced tumour cells. Br. J. Cancer, 74: 1564-1569, 1996.
56. Chemoprevention Working Group. Prevention of cancer in the next millenium: report of the chemoprevention working group to the American Association for Cancer Research. Cancer Res., 59: 4743-4758, 1999.
57. Ehrlich, P. Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd., 5: 273-290, 1909.